BioMarin to Acquire Alesta Therapeutics for Up to $490 Million
BioMarin agreed to acquire privately held Alesta Therapeutics for $275 million upfront in cash plus up to $215 million in development and regulatory milestones. The transaction is centered on ALE1, an oral small molecule…
